BR112012027545A2 - composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo - Google Patents
composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduoInfo
- Publication number
- BR112012027545A2 BR112012027545A2 BR112012027545A BR112012027545A BR112012027545A2 BR 112012027545 A2 BR112012027545 A2 BR 112012027545A2 BR 112012027545 A BR112012027545 A BR 112012027545A BR 112012027545 A BR112012027545 A BR 112012027545A BR 112012027545 A2 BR112012027545 A2 BR 112012027545A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- individual
- formula
- blood glucose
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010156732 | 2010-04-27 | ||
| CN201010156732.1 | 2010-04-27 | ||
| CN201110078365.2 | 2011-03-30 | ||
| CN201110078365 | 2011-03-30 | ||
| PCT/CN2011/000764 WO2011134284A1 (zh) | 2010-04-27 | 2011-04-29 | 胰高血糖素样肽-1类似物及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012027545A2 true BR112012027545A2 (pt) | 2017-03-14 |
| BR112012027545A8 BR112012027545A8 (pt) | 2018-01-02 |
| BR112012027545B1 BR112012027545B1 (pt) | 2020-09-24 |
Family
ID=44860821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012027545-3A BR112012027545B1 (pt) | 2010-04-27 | 2011-04-29 | Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8951959B2 (pt) |
| EP (1) | EP2565205B1 (pt) |
| AU (1) | AU2011247824B2 (pt) |
| BR (1) | BR112012027545B1 (pt) |
| CA (1) | CA2797431C (pt) |
| ES (1) | ES2548259T3 (pt) |
| HK (1) | HK1162037A1 (pt) |
| RU (1) | RU2531590C2 (pt) |
| SG (1) | SG185066A1 (pt) |
| WO (1) | WO2011134284A1 (pt) |
| ZA (1) | ZA201208829B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA022816B1 (ru) | 2009-07-13 | 2016-03-31 | Зилэнд Фарма А/С | Ацилированные аналоги глюкагона |
| WO2013164483A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| PL2875043T3 (pl) | 2012-07-23 | 2017-06-30 | Zealand Pharma A/S | Analogi glukagonu |
| FR2994848B1 (fr) | 2012-08-30 | 2014-08-22 | Univ Paris Curie | Traitement de l'arthrose par les hormones incretines ou leurs analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| SG11201602965WA (en) | 2013-10-17 | 2016-05-30 | Zealand Pharma As | Acylated glucagon analogues |
| US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| CA2929107C (en) | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
| RU2716985C2 (ru) | 2014-10-29 | 2020-03-17 | Зилэнд Фарма А/С | Соединения-агонисты gip и способы |
| WO2016166289A1 (en) | 2015-04-16 | 2016-10-20 | Zealand Pharma A/S | Acylated glucagon analogue |
| CN106928086B (zh) * | 2015-12-31 | 2019-05-31 | 深圳翰宇药业股份有限公司 | 一种长链化合物的制备方法 |
| PL3774862T3 (pl) | 2018-04-05 | 2022-10-03 | Sun Pharmaceutical Industries Limited | Nowe analogi glp-1 |
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2401276C2 (ru) * | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
| CA2539253A1 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CA2550050A1 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
| TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN101128214A (zh) * | 2005-03-18 | 2008-02-20 | 诺和诺德公司 | 长效glp-1化合物 |
| CN103124739B (zh) * | 2010-05-17 | 2015-11-25 | 贝达药业股份有限公司 | 一种新胰高血糖素样肽类似物、组合物及其用途 |
-
2011
- 2011-04-29 AU AU2011247824A patent/AU2011247824B2/en not_active Ceased
- 2011-04-29 RU RU2012150108/04A patent/RU2531590C2/ru active
- 2011-04-29 EP EP11774275.9A patent/EP2565205B1/en active Active
- 2011-04-29 US US13/643,840 patent/US8951959B2/en active Active
- 2011-04-29 ES ES11774275.9T patent/ES2548259T3/es active Active
- 2011-04-29 SG SG2012079661A patent/SG185066A1/en unknown
- 2011-04-29 BR BR112012027545-3A patent/BR112012027545B1/pt not_active IP Right Cessation
- 2011-04-29 CA CA2797431A patent/CA2797431C/en active Active
- 2011-04-29 WO PCT/CN2011/000764 patent/WO2011134284A1/zh active Application Filing
-
2012
- 2012-03-13 HK HK12102503.2A patent/HK1162037A1/xx not_active IP Right Cessation
- 2012-11-22 ZA ZA2012/08829A patent/ZA201208829B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2797431C (en) | 2016-06-21 |
| EP2565205B1 (en) | 2015-07-01 |
| BR112012027545B1 (pt) | 2020-09-24 |
| AU2011247824B2 (en) | 2014-02-13 |
| RU2012150108A (ru) | 2014-06-10 |
| SG185066A1 (en) | 2012-12-28 |
| CA2797431A1 (en) | 2011-11-03 |
| BR112012027545A8 (pt) | 2018-01-02 |
| HK1162037A1 (en) | 2012-08-17 |
| EP2565205A4 (en) | 2013-09-11 |
| US20130053304A1 (en) | 2013-02-28 |
| RU2531590C2 (ru) | 2014-10-20 |
| US8951959B2 (en) | 2015-02-10 |
| EP2565205A1 (en) | 2013-03-06 |
| ES2548259T3 (es) | 2015-10-15 |
| WO2011134284A1 (zh) | 2011-11-03 |
| ZA201208829B (en) | 2013-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012027545A2 (pt) | composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| BRPI0921389A2 (pt) | seringa de um só uso, de inutilização automática | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014007134A2 (pt) | usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto | |
| BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
| BRPI0918360A2 (pt) | composto, composição farmacêutica e usos de um composto | |
| BRPI1014760A2 (pt) | preparacao compreendendo insulina, nicotinamida e um aminoacido | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI0921802A8 (pt) | uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo. | |
| BRPI0913726A2 (pt) | rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos | |
| BR112013015010A2 (pt) | produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana | |
| BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
| BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BR112014010139A2 (pt) | formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo | |
| BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112012026707A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado | |
| DK2350026T3 (da) | Sulfoximinsubstituerede anilinopyrimidinderativer som cdk-inhibitorer, fremstilling og anvendelse heraf som lægemiddel | |
| BR112014013178A2 (pt) | composto, composição farmacêutica e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: BETTA PHARMACEUTICALS CO., LTD. (CN) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |